BCMA Targeted Therapies

Memo

Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite GSK's ADC, Blenrep, gaining approval in 2020 first, BCMA-targeted CAR-T and BiTe therapies continue to find their place. With such a well validated target, rapid advances and growing excitement in the field, the inaugural BCMA Targeted Therapies Summit is industry's first dedicated discussion and networking forum focused on bringing together the thought-leaders within the BCMA field to share the latest scientific progress and address the current challenges drug developers are facing. Developed with experts from Amgen, Kite Pharma and Legend Bio and other leading organizations, join 80+ of your peers and be part of this unique opportunity to engage in cross-industry discussions. Hear from over 20 experts sharing preclinical data for next generation BCMA targeted therapies, bringing in the patient perspective and exploring efficacy of patient response from the clinic. URLs:Tickets: https://go.evvnt.com/727512-2?pid=5569Brochure: https://go.evvnt.com/727512-3?pid=5569 Prices:Drug Developer - Conference + 2 Workshops: USD 2537.0,Drug Developer - Conference + 1 Workshop: USD 2268.0,Drug Developer - Conference Only: USD 1999.0,Academic Pricing - Conference + 2 Workshops: USD 2137.0,Academic Pricing - Conference + 1 Workshop: USD 1968.0,Academic Pricing - Conference Only: USD 1799.0,Service Provider - Conference + 2 Workshops: USD 3237.0,Service Provider - Conference + 1 Workshop: USD 2868.0,Service Provider - Conference Only: USD 2499.0 Speakers: Adam Cohen, Assistant Professor - Medicine, University of Pennsylvania, Andreas Pahl, Chied Scientific Officer, Heidelbeg Pharma, David DiLillo, Assoc. Director, Immuno-Oncology, Regeneron, Deixu Bu, Senior Principal Scientist, Novartis, Duy Pharm, Clinical Development Project Manager, TeneoBio, Farzana Walcott, Associate Director - Clinical Development and Oncology, AstraZeneca, Enrique Zudaire, Scientific Director, JnJ, Hans Chulhee Lee, Assistant Professor, MD Anderson, Heather Van Epps, Associate Director, Antibody Discovery, Seagen, Hong Ma, Senior Vice President - Clinical Development, CARSgen Therapeutics, Krina Patel, Assistant Professor, MD Anderson, Lekha Mikkilineni, Assistant Research Physician, NCI/NIH, Marc Raab, Physician-Scientist and Professor of Medicine at the Heidelberg University Medical Center and Group Leader, German Cancer Research Center (DKFZ), Matthew Spear, Chief Medical Officer, Poseida Therpeutics, Matthias Friedrich, Scientific Director, Amgen, Natalie Sacks, Chief Medical Officer, Harpoon Therapeutics, Noopur Raje, Director - Multiple Myeloma Program and Professor - Medicine, Massachusetts General Hospital, Raluca Verona, Senior Director, Head of Immune Oncology and Translational Research, JnJ, Regina Lin, Principle Scientist, Allogene, Robert Olowski, Professor - Lymphoma and Myeloma and Division of Cancer Medicine, MD Anderson Cancer Centre, Timothy Campbell, Senior Medical Director in Translational Medicine, BMS, Chris Heery, Chief Medical Officer, Precision BioSciences, Inc, Frank Fan, Co-Founder and Chief Scientific Officer, Legend Biotech Date and Time: On Monday June 21, 2021 at 9:00 am (ends Wednesday June 23, 2021 at 4:00 pm)